NuGen Medical Devices Inc.
NGMDF · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 56.8% | -81.1% | -71.9% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 60.9% | 60.2% | 55.3% | 54.1% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $0 | $0 | $0 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -3,444.4% | -4,488.1% | -718.7% | -208.8% |
| Other Income/Exp. Net | -$0 | -$0 | $0 | $0 |
| Pre-Tax Income | -$0 | -$0 | $0 | $0 |
| Tax Expense | -$0 | $0 | $0 | -$0 |
| Net Income | -$0 | -$0 | $0 | $0 |
| % Margin | -5,383.1% | -10,520.5% | 1,339.5% | 122.7% |
| EPS | -0.008 | -0.01 | 0.007 | 0.002 |
| % Growth | 21.6% | -247.8% | 200% | – |
| EPS Diluted | -0.008 | -0.01 | 0.007 | 0.002 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$0 | -$0 | $0 | $0 |
| % Margin | -2,598.1% | -6,429.5% | 2,051.9% | 332% |